Early metabolic changes in breast cancer patients starting hormone therapy
Part of Cancer, Skin clinical trials.
This study looks at how hormone therapy for breast cancer affects your body's metabolism, such as blood sugar and cholesterol. It aims to understand these changes early so doctors can better support your health during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with invasive breast cancer that is hormone receptor-positive (ER+).
- You are not currently taking medication for diabetes.
- You are about to start adjuvant endocrine therapy (hormone therapy) as part of your breast cancer treatment.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how standard breast cancer treatments affect your body’s metabolism and bones in postmenopausal people with early-stage breast cancer. It may help doctors better predict and prevent bone and metabolic side effects from treatment.
This study follows how “metabolic health” patterns (like eating timing and daily activity) change over time during breast cancer care. It may help researchers learn which habit patterns are linked to better outcomes and comfort during chemotherapy.
This study looks at the eating habits, nutrition knowledge, and physical activity of women with early-stage breast cancer. It aims to understand how these factors relate to your health and recovery after surgery.
This study looks at how starting a common hormone therapy for breast cancer (aromatase inhibitors) affects your heart and brain health over the short term. It compares women starting this treatment to healthy women who are not on the therapy.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This study looks at how a hormone-blocking medicine (endocrine therapy) given before surgery affects a marker called Ki67 in your breast cancer cells. The goal is to see if the medicine can slow the growth of the cancer, which may help doctors choose the best treatment for you.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.